Relevance of tumor markers for prognosis and predicting therapy response in non-small cell lung cancer patients: A CEPAC-TDM biomarker substudy.

Q3 Biochemistry, Genetics and Molecular Biology

Tumor Biology Pub Date : 2024-01-01 DOI:10.3233/TUB-230014

Kimberly Geiger, Markus Joerger, Max Roessler, Karina Hettwer, Christoph Ritter, Kirsten Simon, Steffen Uhlig, Stefan Holdenrieder

{"title":"Relevance of tumor markers for prognosis and predicting therapy response in non-small cell lung cancer patients: A CEPAC-TDM biomarker substudy.","authors":"Kimberly Geiger, Markus Joerger, Max Roessler, Karina Hettwer, Christoph Ritter, Kirsten Simon, Steffen Uhlig, Stefan Holdenrieder","doi":"10.3233/TUB-230014","DOIUrl":null,"url":null,"abstract":"Background: Protein tumor markers are released in high amounts into the blood in advanced non-small cell lung cancer (NSCLC).Objective: To investigate the relevance of serum tumor markers (STM) for prognosis, prediction and monitoring of therapy response in NSCLC patients receiving chemotherapy.Methods: In a biomarker substudy of a prospective, multicentric clinical trial (CEPAC-TDM) on 261 advanced NSCLC patients, CYFRA 21-1, CEA, SCC, NSE, ProGRP, CA125, CA15-3 and HE4 were assessed in serial serum samples and correlated with radiological response after two cycles of chemotherapy and overall (OS) and progression-free survival (PFS).Results: While pretherapeutic STM levels at staging did not discriminate between progressive and non-progressive patients, CYFRA 21-1, CA125, NSE and SCC at time of staging did, and yielded AUCs of 0.75, 0.70, 0.69 and 0.67 in ROC curves, respectively. High pretherapeutic CA15-3 and CA125 as well as high CYFRA 21-1, SCC, CA125 and CA15-3 levels at staging were prognostic for shorter PFS and OS -also when clinical variables were added to the models.Conclusions: STM at the time of first radiological staging and pretherapeutic CA15-3, CA125 are predictive for first-line treatment response and highly prognostic in patients with advanced NSCLC.","PeriodicalId":23364,"journal":{"name":"Tumor Biology","volume":" ","pages":"S191-S206"},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Tumor Biology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3233/TUB-230014","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Biochemistry, Genetics and Molecular Biology","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Protein tumor markers are released in high amounts into the blood in advanced non-small cell lung cancer (NSCLC).

Objective: To investigate the relevance of serum tumor markers (STM) for prognosis, prediction and monitoring of therapy response in NSCLC patients receiving chemotherapy.

Methods: In a biomarker substudy of a prospective, multicentric clinical trial (CEPAC-TDM) on 261 advanced NSCLC patients, CYFRA 21-1, CEA, SCC, NSE, ProGRP, CA125, CA15-3 and HE4 were assessed in serial serum samples and correlated with radiological response after two cycles of chemotherapy and overall (OS) and progression-free survival (PFS).

Results: While pretherapeutic STM levels at staging did not discriminate between progressive and non-progressive patients, CYFRA 21-1, CA125, NSE and SCC at time of staging did, and yielded AUCs of 0.75, 0.70, 0.69 and 0.67 in ROC curves, respectively. High pretherapeutic CA15-3 and CA125 as well as high CYFRA 21-1, SCC, CA125 and CA15-3 levels at staging were prognostic for shorter PFS and OS -also when clinical variables were added to the models.

Conclusions: STM at the time of first radiological staging and pretherapeutic CA15-3, CA125 are predictive for first-line treatment response and highly prognostic in patients with advanced NSCLC.

查看原文本刊更多论文

肿瘤标志物与非小细胞肺癌患者预后和治疗反应预测的相关性：CEPAC-TDM生物标志物子研究。

背景：晚期非小细胞肺癌（NSCLC）患者的血液中会释放大量蛋白质肿瘤标志物：晚期非小细胞肺癌（NSCLC）患者的血液中会释放大量蛋白质肿瘤标志物：目的：研究血清肿瘤标志物（STM）对接受化疗的非小细胞肺癌患者的预后、预测和治疗反应监测的相关性：在一项针对 261 名晚期 NSCLC 患者的前瞻性多中心临床试验（CEPAC-TDM）的生物标志物子研究中，对连续血清样本中的 CYFRA 21-1、CEA、SCC、NSE、ProGRP、CA125、CA15-3 和 HE4 进行了评估，并将其与两个化疗周期后的放射学反应以及总生存期（OS）和无进展生存期（PFS）相关联：分期时的治疗前 STM 水平不能区分进展期和非进展期患者，而分期时的 CYFRA 21-1、CA125、NSE 和 SCC 却能区分进展期和非进展期患者，在 ROC 曲线中的 AUC 分别为 0.75、0.70、0.69 和 0.67。治疗前的高CA15-3和CA125水平以及分期时的高CYFRA 21-1、SCC、CA125和CA15-3水平是较短PFS和OS的预后指标--当临床变量被添加到模型中时也是如此：结论：首次放射学分期时的 STM 和治疗前的 CA15-3、CA125 可预测晚期 NSCLC 患者的一线治疗反应和预后。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Tumor Biology 医学-肿瘤学

CiteScore

5.40

自引率

0.00%

发文量

审稿时长

1 months

期刊介绍： Tumor Biology is a peer reviewed, international journal providing an open access forum for experimental and clinical cancer research. Tumor Biology covers all aspects of tumor markers, molecular biomarkers, tumor targeting, and mechanisms of tumor development and progression. Specific topics of interest include, but are not limited to: Pathway analyses, Non-coding RNAs, Circulating tumor cells, Liquid biopsies, Exosomes, Epigenetics, Cancer stem cells, Tumor immunology and immunotherapy, Tumor microenvironment, Targeted therapies, Therapy resistance Cancer genetics, Cancer risk screening. Studies in other areas of basic, clinical and translational cancer research are also considered in order to promote connections and discoveries across different disciplines. The journal publishes original articles, reviews, commentaries and guidelines on tumor marker use. All submissions are subject to rigorous peer review and are selected on the basis of whether the research is sound and deserves publication. Tumor Biology is the Official Journal of the International Society of Oncology and BioMarkers (ISOBM).